These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 28549133)

  • 1. Drug repurposing to target proteostasis and prevent neurodegeneration: accelerating translational efforts.
    Mercado G; Hetz C
    Brain; 2017 Jun; 140(6):1544-1547. PubMed ID: 28549133
    [No Abstract]   [Full Text] [Related]  

  • 2. Trazodone to change the risk of neurodegeneration: bedside to bench.
    Camargos EF; Nóbrega OT
    Brain; 2017 Aug; 140(8):e47. PubMed ID: 28641375
    [No Abstract]   [Full Text] [Related]  

  • 3. Neurodegenerative disease: Halting neurodegeneration - are repurposed drugs the answer?
    Wood H
    Nat Rev Neurol; 2017 Jun; 13(6):317. PubMed ID: 28474684
    [No Abstract]   [Full Text] [Related]  

  • 4. Reply: Trazodone to change the risk of neurodegeneration: bedside to bench.
    Halliday M; Mallucci GR
    Brain; 2017 Aug; 140(8):e48. PubMed ID: 28641370
    [No Abstract]   [Full Text] [Related]  

  • 5. Accelerating Precision Drug Development and Drug Repurposing by Leveraging Human Genetics.
    Pulley JM; Shirey-Rice JK; Lavieri RR; Jerome RN; Zaleski NM; Aronoff DM; Bastarache L; Niu X; Holroyd KJ; Roden DM; Skaar EP; Niswender CM; Marnett LJ; Lindsley CW; Ekstrom LB; Bentley AR; Bernard GR; Hong CC; Denny JC
    Assay Drug Dev Technol; 2017 Apr; 15(3):113-119. PubMed ID: 28379727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The moment when translational control had a theory of everything.
    Jacobson A
    Nat Rev Mol Cell Biol; 2017 Jun; 18(6):344. PubMed ID: 28400611
    [No Abstract]   [Full Text] [Related]  

  • 7. Proteomic Analysis of eIF5B Silencing-Modulated Proteostasis.
    Jiang X; Jiang X; Feng Y; Xu R; Wang Q; Deng H
    PLoS One; 2016; 11(12):e0168387. PubMed ID: 27959964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mapping and Exploring the Collagen-I Proteostasis Network.
    DiChiara AS; Taylor RJ; Wong MY; Doan ND; Rosario AM; Shoulders MD
    ACS Chem Biol; 2016 May; 11(5):1408-21. PubMed ID: 26848503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances in quantitative and chemical proteomics for autophagy studies.
    Wong YK; Zhang J; Hua ZC; Lin Q; Shen HM; Wang J
    Autophagy; 2017 Sep; 13(9):1472-1486. PubMed ID: 28820289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Revisiting Repurposing.
    Sharlow ER
    Assay Drug Dev Technol; 2016 Dec; 14(10):554-556. PubMed ID: 27982703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-enzymatic post-translational protein modifications and proteostasis network deregulation in carcinogenesis.
    Trougakos IP; Sesti F; Tsakiri E; Gorgoulis VG
    J Proteomics; 2013 Oct; 92():274-98. PubMed ID: 23500136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aberration in translation initiation and associated diseases: Role of the eukaryotic translation initiation factor 3A.
    Zhu T; Gao Y; Li L; Wang L; Yin J; Zhou H; Zhang W; Liu Z
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2017 Oct; 42(10):1204-1211. PubMed ID: 29093254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic approaches to identify E3 ligase substrates.
    Iconomou M; Saunders DN
    Biochem J; 2016 Nov; 473(22):4083-4101. PubMed ID: 27834739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Keeping up the balance: role of HDACs in cardiac proteostasis and therapeutic implications for atrial fibrillation.
    Zhang D; Hu X; Henning RH; Brundel BJ
    Cardiovasc Res; 2016 Apr; 109(4):519-26. PubMed ID: 26645980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of muscular dystrophy, exercise and blocking activin receptor IIB ligands on the unfolded protein response and oxidative stress.
    Hulmi JJ; Hentilä J; DeRuisseau KC; Oliveira BM; Papaioannou KG; Autio R; Kujala UM; Ritvos O; Kainulainen H; Korkmaz A; Atalay M
    Free Radic Biol Med; 2016 Oct; 99():308-322. PubMed ID: 27554968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In silico drug repositioning: what we need to know.
    Liu Z; Fang H; Reagan K; Xu X; Mendrick DL; Slikker W; Tong W
    Drug Discov Today; 2013 Feb; 18(3-4):110-5. PubMed ID: 22935104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repurposing of Potent Drug Candidates for Multiparasite Targeting.
    Jain V; Sharma A
    Trends Parasitol; 2017 Mar; 33(3):158-161. PubMed ID: 28081985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug discovery and repurposing at Memorial Sloan Kettering Cancer Center: chemical biology drives translational medicine.
    Bhinder B; Djaballah H
    ACS Chem Biol; 2014 Jul; 9(7):1394-7. PubMed ID: 25033723
    [No Abstract]   [Full Text] [Related]  

  • 19. Challenges and recommendations for obtaining chemical structures of industry-provided repurposing candidates.
    Southan C; Williams AJ; Ekins S
    Drug Discov Today; 2013 Jan; 18(1-2):58-70. PubMed ID: 23159359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rational application of drug promiscuity in medicinal chemistry.
    Mei Y; Yang B
    Future Med Chem; 2018 Aug; 10(15):1835-1851. PubMed ID: 30019924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.